The trajectory of Viagra presents a interesting case for observers in the drug sector. While initially a phenomenal success, creating huge profits, the patent end and the subsequent flood of off-brand competitors have significantly affected revenue. This presents questions about the ongoing profitability of analogous therapeutic innovations and sug